Intra-Cellular Therapies PE Ratio 2013-2022 | ITCI
Current and historical p/e ratio for Intra-Cellular Therapies (ITCI) from 2013 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Intra-Cellular Therapies PE ratio as of May 25, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Intra-Cellular Therapies PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-05-25 |
56.67 |
|
0.00 |
| 2022-03-31 |
61.19 |
$-3.63 |
0.00 |
| 2021-12-31 |
52.34 |
$-3.50 |
0.00 |
| 2021-09-30 |
37.28 |
$-3.21 |
0.00 |
| 2021-06-30 |
40.82 |
$-3.05 |
0.00 |
| 2021-03-31 |
33.93 |
$-3.16 |
0.00 |
| 2020-12-31 |
31.80 |
$-3.24 |
0.00 |
| 2020-09-30 |
25.66 |
$-3.22 |
0.00 |
| 2020-06-30 |
25.67 |
$-3.06 |
0.00 |
| 2020-03-31 |
15.37 |
$-2.78 |
0.00 |
| 2019-12-31 |
34.31 |
$-2.68 |
0.00 |
| 2019-09-30 |
7.47 |
$-2.69 |
0.00 |
| 2019-06-30 |
12.98 |
$-2.82 |
0.00 |
| 2019-03-31 |
12.18 |
$-2.82 |
0.00 |
| 2018-12-31 |
11.39 |
$-2.84 |
0.00 |
| 2018-09-30 |
21.70 |
$-2.65 |
0.00 |
| 2018-06-30 |
17.67 |
$-2.42 |
0.00 |
| 2018-03-31 |
21.05 |
$-2.15 |
0.00 |
| 2017-12-31 |
14.48 |
$-2.12 |
0.00 |
| 2017-09-30 |
15.78 |
$-2.20 |
0.00 |
| 2017-06-30 |
12.42 |
$-2.37 |
0.00 |
| 2017-03-31 |
16.25 |
$-2.67 |
0.00 |
| 2016-12-31 |
15.09 |
$-2.69 |
0.00 |
| 2016-09-30 |
15.24 |
$-2.72 |
0.00 |
| 2016-06-30 |
38.82 |
$-2.93 |
0.00 |
| 2016-03-31 |
27.80 |
$-2.83 |
0.00 |
| 2015-12-31 |
53.79 |
$-2.91 |
0.00 |
| 2015-09-30 |
40.04 |
$-2.76 |
0.00 |
| 2015-06-30 |
31.95 |
$-2.07 |
0.00 |
| 2015-03-31 |
23.88 |
$-1.61 |
0.00 |
| 2014-12-31 |
17.65 |
$-1.06 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.373B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
